|
| 36367998 | Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. | J Clin Oncol | 2023 |
| 37211963 | Test-retest repeatability of organ uptake on PSMA-targeted <sup>18</sup> F-DCFPyL PET/CT in patients with prostate cancer. | Prostate | 2023 |
| 36857019 | Multi-timepoint imaging with PSMA-targeted [<sup>18</sup>F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging. | Ann Nucl Med | 2023 |
| 36632656 | Lack of repeatability of radiomic features derived from PET scans: Results from a <sup>18</sup> F-DCFPyL test-retest cohort. | Prostate | 2023 |
| 35283693 | High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with <sup>18</sup>F-DCFPyL. | Mol Imaging | 2022 |
| 35677318 | Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. | Ther Adv Med Oncol | 2022 |
| 35538398 | Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. | Prostate | 2022 |
| 35416959 | A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent. | Clin Cancer Res | 2022 |
| 32536574 | Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. | Eur Urol Oncol | 2021 |
| 33740734 | An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. | ESMO Open | 2021 |
| 33904646 | Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. | Oncologist | 2021 |
| 33617303 | TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. | J Clin Oncol | 2021 |
| 33805793 | Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study. | Cancers (Basel) | 2021 |
| 33636027 | Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial. | Prostate | 2021 |
| 33608426 | Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. | J Nucl Med | 2021 |
| 34103179 | Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. | Eur Urol | 2021 |
| 34337548 | Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. | Eur Urol Open Sci | 2021 |
| 34003011 | Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. | J Urol | 2021 |
| 33452039 | Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. | J Nucl Med | 2021 |
| 33419682 | The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. | Eur Urol | 2021 |
| 33383350 | Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. | Eur J Cancer | 2021 |
| 32798608 | Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2021 |
| 32624280 | A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. | Eur Urol | 2021 |
| 31176623 | Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. | Eur Urol | 2020 |
| 31837907 | Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. | Eur J Cancer | 2020 |
| 32807727 | Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. | Eur Urol Oncol | 2020 |
| 32250727 | Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on <sup>18</sup>F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. | J Urol | 2020 |
| 32389660 | Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. | Hum Pathol | 2020 |
| 32215577 | Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. | JAMA Oncol | 2020 |
| 32552276 | Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. | J Clin Oncol | 2020 |
| 32487038 | A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). | BMC Cancer | 2020 |
| 32289380 | Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. | Ann Oncol | 2020 |
| 32368717 | Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. | JNCI Cancer Spectr | 2020 |
| 30301829 | Expression of AR-V7 and ARv<sup>567es</sup> in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. | Clin Cancer Res | 2019 |
| 31881143 | Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer - Playing the Right CARD. | N Engl J Med | 2019 |
| 31650100 | Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. | JCO Precis Oncol | 2019 |
| 30191396 | Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. | World J Urol | 2019 |
| 31389628 | Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype. | Prostate | 2019 |
| 31530439 | PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. | Clin Genitourin Cancer | 2019 |
| 31483709 | Progress in the Systemic Management of Advanced Prostate Cancer: The Hormone-Sensitive Paradigm. | J Clin Oncol | 2019 |
| 31196032 | A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). | BMC Cancer | 2019 |
| 31419509 | Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. | Int J Radiat Oncol Biol Phys | 2019 |
| 31361358 | A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. | Prostate | 2019 |
| 30797618 | Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. | Eur Urol | 2019 |
| 30851334 | TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. | Hum Pathol | 2019 |
| 30725389 | A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. | Invest New Drugs | 2019 |
| 31131348 | Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. | JCO Precis Oncol | 2019 |
| 30576268 | Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. | J Clin Oncol | 2019 |
| 30293905 | Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. | Eur Urol | 2019 |
| 30286948 | Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. | Eur Urol | 2019 |